Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraventricular Nivolumab with Methotrexate or 5-Azacytidine for Recurrent CNS Malignancies
NCT06466798Phase 1Withdrawn
- Start
- Jul 2024
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of nivolumab in medulloblastoma, ependymoma and central nervous system malignancy (2 arms). Primary endpoint: Dose-Limiting Toxicity at 12 weeks. Planned start Jul 2024; status: withdrawn.
02
Drugs
03
Conditions
medulloblastomaependymomacentral nervous system malignancy
Beyond the preview
Go deeper on NCT06466798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06466798.